An event is serious (FDA MedWatch definition) when the patient outcome is:deathlife-threateninghospitalisationdisabilitycongenital anomalyrequires intervention to prevent permanent impairment or damage

A 67-year-old woman, with inclusion body myositis secondary to human T-cell lymphotrophic virus, developed refractory hypokalaemia and hypomagnesaemia during hydrochlorothiazide treatment for hypertension.

The woman, who was receiving hydrochlorothiazide 25 mg/day, presented with headache and high BP and her dose was increased to 50 mg/day \[*route not stated*\]. Confusion and a change in mentation were noted 4 days later. She had been concomitantly taking both doses of hydrochlorothiazide. She was admitted to the ICU for symptomatic hyponatraemia.

The woman\'s mental status gradually improved with hypertonic sodium chloride administration. Bibasilar pneumonia was revealed by x-ray. On her second day, she developed acute-on-chronic respiratory failure, requiring intubation and mechanical ventilation. She went on to develop septic shock, adult respiratory distress syndrome (ARDS), thrombocytopenia and coagulopathy. ARDS and septic shock resolved by the second week in ICU. A tracheotomy was performed. She had persistent hypomagnesaemia, hypokalaemia and hypocalcaemia during her hospital stay. Renal potassium wasting was indicated by a transtubular potassium gradient of 9. Hypokalaemia persisted despite potassium, magnesium and calcium electrolyte replacement. At last follow-up, her electrolyte levels were monitored daily with additional replacements required for low potassium levels.***Author Comment***"Hydrochlorothiazide was attributed as the causal agent for refractory hypokalaemia and hypomagnesaemia and the hypocalcaemia was attributed to Vitamin D deficiency."
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